The rise of injectable weight-loss medications over the past three years has started to reshape everyday social habits in ways that extend far beyond the bathroom scale. Observers tracking the cultural impact of drugs such as Mounjaro, Wegovy and Ozempic point to measurable shifts in consumer behaviour, including rising chewing gum sales, declining phone scrolling and a new, unspoken etiquette at social gatherings where guests discreetly hide food in napkins.
The changes reflect how a class of medicines originally developed for type 2 diabetes has moved into mainstream use for weight management, altering not only individual health outcomes but also the rhythms of daily life. As millions of people take these drugs, which suppress appetite and slow digestion, their relationship with food, social occasions and even digital habits is being transformed in ways that few predicted when the treatments first gained popularity.
One of the most visible trends is the surge in chewing gum sales. People on GLP-1 medications often experience dry mouth, a common side effect, and many turn to gum to manage the sensation. At the same time, the drugs reduce the desire to snack, so gum serves as a substitute for mindless eating. Retail data suggests that gum purchases have climbed steadily as prescriptions for weight-loss injections have risen, creating an unexpected beneficiary in the confectionery aisle.
Phone scrolling, by contrast, appears to be declining among users of these medications. Health professionals and behavioural researchers note that the compulsive urge to scroll through social media feeds often parallels the urge to eat: both are reward-seeking behaviours driven by dopamine. When appetite-suppressing drugs dampen food cravings, some patients report a corresponding reduction in other impulsive habits, including endless phone use. The phenomenon has intrigued psychologists, who see it as evidence that the medications may influence broader reward pathways in the brain, not just hunger signals.
At parties and dinners, a quieter shift is taking place. Hosts and guests alike describe a new social choreography in which people on weight-loss drugs discreetly push food around their plates, wrap portions in napkins or quietly dispose of dishes they cannot finish. The behaviour stems from the drugs' effect on gastric emptying: eating too much can cause nausea or discomfort, so individuals develop strategies to avoid offending hosts while protecting their own wellbeing. What was once a private medical choice has become a visible, if unspoken, feature of communal dining.
The social consequences extend to how people plan events. Caterers and party planners report growing demand for smaller portions, lighter menus and more non-alcoholic options, as hosts accommodate guests whose eating and drinking habits have changed. Alcohol consumption, in particular, has dropped among users of these medications, partly because the drugs make drinking less appealing and partly because many people on weight-loss programmes are consciously reducing calorie intake from all sources.
Three years into the widespread availability of these treatments, the cumulative effect on daily routines is becoming clearer. What began as a medical intervention for obesity has evolved into a cultural phenomenon with ripple effects across consumer markets, social norms and personal habits. Chewing gum manufacturers, app developers and even etiquette writers are taking note, adjusting their products and advice to a population whose relationship with food and pleasure is undergoing a fundamental shift.
None of this was anticipated when the first wave of prescriptions was issued. The drugs were expected to change bodies; what is now evident is that they are also changing behaviour, sometimes in subtle and surprising ways that researchers are only beginning to map.